End-of-day quote. End-of-day quote  - 11/26
1.075AUD -7.73%

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

06/11/2021 | 12:27am
Starpharma announced it had received confirmation that VIRALEZETM antiviral nasal spray has been registered for sale nationally in India via the Central Drugs Standard Control Organisation (CDSCO), which is part of the Indian Ministry of Health and Family Welfare. Consumers in India can currently purchase VIRALEZE TM via, and discussions to finalise local distribution arrangements with potential commercial partners into both the private (consumer) and Government markets are well advanced. Starpharma is also progressing product supply preparations for the Indian market. VIRALEZETM is an easy-to-use antiviral nasal spray, which can be stored at room temperature and does not require cold storage or specialised transportation. It contains SPL7013 (astodrimer sodium), which has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.9% of coronavirus SARS-CoV-2 (the virus that causes COVID-19). SPL7013 has been shown to be virucidal, rapidly inactivating >99.9% of SARS-CoV-2 within 60 seconds with potent antiviral activity shown in multiple strains and variants of the virus. The active in VIRALEZETM has also been shown to be highly active against multiple strains and variants of SARS-CoV-2, including the Alpha variant, a Variant of Concern, which is the second most common variant reported in India 5 and has been responsible for COVID-19 cases in ~135 countries to date 6. Further testing is underway with other Variants of Concern. VIRALEZETM antiviral nasal spray complements other COVID-19 prevention strategies, including vaccines. It has special relevance in areas of high population density, and where social distancing is not possible and in high-risk environments like travel, hotel quarantine, and sporting events (e.g. Cricket matches, Olympics etc).
© S&P Capital IQ 2021
Copier lien
2d ago